Hematologic Malignancy
Transformed Non-Hodgkin Lymphoma
CI-CAN-00004142Explore in graph →
Hematologic43 active trials
- NCIt
- C151957
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004142Explore in graph →
Clinical trials
75 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03380026 | Mechlorethamine Induced Contact Dermatitis Avoidance Study(MIDAS) | completed | Phase 2 | 28 | Rochester Skin Lymphoma Medical Group, PLLCOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04930653 | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06784726 | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | active not recruiting | Phase 1 | 52 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03440567 | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06486051 | A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma(ENABLE-2) | recruiting | Phase 2 | 60 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05821088 | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | active not recruiting | Phase 2 | 37 | David Bond, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | not yet recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06854159 | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | recruiting | Phase 2 | 34 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04850495 | Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 | 38 | Yazeed SawalhaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | recruiting | Phase 2 | 25 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | recruiting | Phase 1 | 36 | C. Babis AndreadisOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07220187 | Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial | not yet recruiting | Phase 3 | 102 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | not yet recruiting | Phase 1 | 29 | Northside Hospital, Inc.OTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06271057 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | recruiting | Phase 2 | 65 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05412290 | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | recruiting | Phase 2 | 31 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04703686 | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | completed | Phase 2 | 67 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07042438 | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells | recruiting | Phase 2 | 56 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05873712 | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | recruiting | Phase 2 | 24 | Aseel AlsouqiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04319237 | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | completed | — | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | terminated | Phase 2 | 23 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04067414 | Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma | completed | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03749018 | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 30 | David Bond, MDOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials